Oxford Nanopore, and Day Zero Diagnostics (DZD), announced a collaboration to develop an end-to-end solution for the diagnosis of bloodstream infections, a leading cause of sepsis.

The mechanism targets both integrated virus and cccDNA; expected to begin clinical testing by end of 2024. Preclinical program data to be presented at the 2023 Hep DART Conference .

A multitude of resistance genes in crop genomes could be brought back to life.

New NGS assay delivers exceptional coverage, providing a rapid and highly sensitive means of investigating MRD in AML samples.

Agreement is part of Veracyte’s multi-platform strategy for its decentralized IVD tests outside of the U.S.

Proteintech Genomics, a subsidiary of Proteintech Group, inc., and a provider of multiomic solutions for single-cell and spatial analysis, announced the launch of the MultiPro™ Human Fixed Cell Immune Profiling Antibody Cocktail.

Assays focus on accelerating cancer research.

Our packed agenda will highlight how the Oxford Nanopore platform can generate richer data revealing enhanced biological insights not possible with short read sequencing – or other sequencing platforms – to accelerate research into human disease.

The partners will offer an integrated sample-to-report rapid nanopore sequencing analysis platform for neonatal/paediatric intensive care units to support clinicians in acute settings.

CEO Gordon Sanghera discusses how Apple’s latest product announcement means complex processing required for DNA/RNA sequencing can now be run from the latest MacBook Pro™ or iMac ™.